<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Phio Pharmaceuticals Corp — News on 6ix</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp</link>
<description>Latest news and press releases for Phio Pharmaceuticals Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/phio-pharmaceuticals-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ac8378dffbe2df10e059.webp</url>
<title>Phio Pharmaceuticals Corp</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp</link>
</image>
<item>
<title>Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-nobel-prize-winning-science-takes-on-skin-cancer-in-a-fireside-chat-with-force-family-office-on-wednesday-april-15-2026</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-nobel-prize-winning-science-takes-on-skin-cancer-in-a-fireside-chat-with-force-family-office-on-wednesday-april-15-2026</guid>
<pubDate>Mon, 13 Apr 2026 11:00:00 GMT</pubDate>
<description>Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert Bitterman, Phio Pharmaceuticals and Steven Saltzstein, Force Family OfficeKing of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene...</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-presentation-at-centri-capital-conference-on-april-14-2026</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-presentation-at-centri-capital-conference-on-april-14-2026</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Investors and Advisors, and Life Sciences Analysts are Invited to Attend the New York City Event; Virtual Webcast Link Available Below King of Prussia,</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-agreement-with-us-cgmp-manufacturing-source-for-drug-product-ph-762</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-agreement-with-us-cgmp-manufacturing-source-for-drug-product-ph-762</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous Carcinomas King of Prussia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - Phio</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-american-academy-of-dermatology-2026-presentation-featuring-clinical-study-results-from-study-of-ph-762-for-cutaneous-carcinoma-underscoring-clinical-pipeline-advancement</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-american-academy-of-dermatology-2026-presentation-featuring-clinical-study-results-from-study-of-ph-762-for-cutaneous-carcinoma-underscoring-clinical-pipeline-advancement</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunotherapy Candidate on March 28, 2026 at 3 PM (MDT) King of</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-a-groundbreaking-approach-to-treating-skin-cancer-in-a-fireside-chat-with-force-family-office</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-a-groundbreaking-approach-to-treating-skin-cancer-in-a-fireside-chat-with-force-family-office</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an</description>
</item>
<item>
<title>Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-march-12-2026-11-am-edt-28</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-march-12-2026-11-am-edt-28</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live,</description>
</item>
<item>
<title>Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-march-12-2026-11-am-edt-29</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-march-12-2026-11-am-edt-29</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live,</description>
</item>
<item>
<title>Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-reports-2025-year-end-financial-results-and-business-update-65</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-reports-2025-year-end-financial-results-and-business-update-65</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings</description>
</item>
<item>
<title>Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-corp-selected-as-b2i-digital-featured-company</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-corp-selected-as-b2i-digital-featured-company</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>Phase 1b Trial Reported Approximately 65% Pathological Response in cSCC, Including Complete Responses at Maximum Dose, With No Serious Adverse Events FDA</description>
</item>
<item>
<title>Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-aligns-leadership-team-to-support-next-stage-development-of-ph-762-and-advancement-of-ph-894</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-aligns-leadership-team-to-support-next-stage-development-of-ph-762-and-advancement-of-ph-894</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals Corp....</description>
</item>
<item>
<title>Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-announces-safety-monitoring-committees-120000262</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-announces-safety-monitoring-committees-120000262</guid>
<pubDate>Tue, 10 Feb 2026 12:00:00 GMT</pubDate>
<description>Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation CohortsKing of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing...</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-participation-third-131500358</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-participation-third-131500358</guid>
<pubDate>Mon, 26 Jan 2026 13:15:00 GMT</pubDate>
<description>Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic..</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-key-tumor-143000698</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-key-tumor-143000698</guid>
<pubDate>Tue, 20 Jan 2026 14:30:00 GMT</pubDate>
<description>Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today a summary of the pathology...</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-participation-sidoti-134500307</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-participation-sidoti-134500307</guid>
<pubDate>Thu, 15 Jan 2026 13:45:00 GMT</pubDate>
<description>Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary...</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-significant-step-134500190</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-significant-step-134500190</guid>
<pubDate>Tue, 23 Dec 2025 13:45:00 GMT</pubDate>
<description>Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a major step forward in its drug development program for PH-762. The company will begin a toxicology...</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-completion-enrollment-163000948</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-completion-enrollment-163000948</guid>
<pubDate>Tue, 25 Nov 2025 16:30:00 GMT</pubDate>
<description>King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-upcoming-podium-134500560</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-upcoming-podium-134500560</guid>
<pubDate>Mon, 17 Nov 2025 13:45:00 GMT</pubDate>
<description>Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania...</description>
</item>
<item>
<title>Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-reports-third-quarter-211500400</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-reports-third-quarter-211500400</guid>
<pubDate>Thu, 13 Nov 2025 21:15:00 GMT</pubDate>
<description>Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third PatientSafety Monitoring Committee Issues Favorable Review of Safety Data at Maximum Dose of INTASYL PH-762Warrant Inducement Financing in November 2025 for Expected Net Proceeds...</description>
</item>
<item>
<title>Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-present-recent-clinical-153000160</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-present-recent-clinical-153000160</guid>
<pubDate>Fri, 07 Nov 2025 15:30:00 GMT</pubDate>
<description>Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society.</description>
</item>
<item>
<title>Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program</title>
<link>https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-intasyl-ph-124500896</link>
<guid isPermaLink="true">https://6ix.com/company/phio-pharmaceuticals-corp/news/phio-pharmaceuticals-announces-intasyl-ph-124500896</guid>
<pubDate>Fri, 07 Nov 2025 12:45:00 GMT</pubDate>
<description>King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award.This is the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading...</description>
</item>
</channel>
</rss>